Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP578944.RAgflEOGxzPIGaOx83f77m11-jx0ziPORBIh9_pzQG1qM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP578944.RAgflEOGxzPIGaOx83f77m11-jx0ziPORBIh9_pzQG1qM130_assertion type Assertion NP578944.RAgflEOGxzPIGaOx83f77m11-jx0ziPORBIh9_pzQG1qM130_head.
- NP578944.RAgflEOGxzPIGaOx83f77m11-jx0ziPORBIh9_pzQG1qM130_assertion description "[In addition to Herceptin, which is in a wide clinical use for HER-2 amplified breast cancer, a number of various HER-2 directed immunological and genetic strategies, either targeting the HER-2 receptor, its signaling pathways or both HER-2 and epidermal growth factor receptor (EGFR) simultaneously, have demonstrated promising pre-clinical activity in HER-2 amplified carcinomas.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP578944.RAgflEOGxzPIGaOx83f77m11-jx0ziPORBIh9_pzQG1qM130_provenance.
- NP578944.RAgflEOGxzPIGaOx83f77m11-jx0ziPORBIh9_pzQG1qM130_assertion evidence source_evidence_literature NP578944.RAgflEOGxzPIGaOx83f77m11-jx0ziPORBIh9_pzQG1qM130_provenance.
- NP578944.RAgflEOGxzPIGaOx83f77m11-jx0ziPORBIh9_pzQG1qM130_assertion SIO_000772 17100565 NP578944.RAgflEOGxzPIGaOx83f77m11-jx0ziPORBIh9_pzQG1qM130_provenance.
- NP578944.RAgflEOGxzPIGaOx83f77m11-jx0ziPORBIh9_pzQG1qM130_assertion wasDerivedFrom befree-2016 NP578944.RAgflEOGxzPIGaOx83f77m11-jx0ziPORBIh9_pzQG1qM130_provenance.
- NP578944.RAgflEOGxzPIGaOx83f77m11-jx0ziPORBIh9_pzQG1qM130_assertion wasGeneratedBy ECO_0000203 NP578944.RAgflEOGxzPIGaOx83f77m11-jx0ziPORBIh9_pzQG1qM130_provenance.